Longevity Dealflow team Scientific evaluation: Sebastian Brunemeier, Tim Peterson, Rhys Anderson, Koen De Lombaert Business evaluation: Sebastian Brunemeier, Tim Peterson Shepherd/Sourced by: Tyler Stahl Squad members: Paolo Binetti, Rhys Anderson, Rakhan Aimbetov, Ryan Spangler Project PI: Ver…

Excellent write up @tylerstahl !! This needs milestones and timeline to achieve payouts. Also the $ quoted should be “up to”. If HTS doesn’t cost $100K, VitaDAO shouldn’t feel obligated to spend $100k. Similarly, some clarity around how long the $5k/month consulting arrangement is expected to last b…

I think the HTS is premature-- if the existing active inhibitor does not work, the whole project is dead in the water. Given the later publications from the PI’s lab, HA is at best one part of a much bigger picture. I am skeptical that an HA inhibitor will work in any real cancer model. DNA integri…

Per @longevion , I had the wrong settings for the poll. Once I have the correct markdown command, I will reopen the poll.

Okay the poll should be corrected. Apologies for any confusion

Thanks @tylerstahl @everyone please vote again

The PI has agreed to perform additional experiments in her lab with the natural product hit compound, and a pilot cancer model is certainly on the table. Which model would you like to see? There is unpublished target engagement data from this NP, but the compound is not very potent. Finding more po…

For initial proof of concept, I’m not married to any particular model, as long as it looks good. Depending on their conviction, trying a couple models might be needed. All the models have pros and cons. I would expect a shorter model for the initial study to justify the time and effort going into lo…

Do we have any sense of a clinical strategy here? What tumor types do we think are the most promising and is there any evidence of where to take any hits we find? How are we doing diligence on CROs also to perform HTS? Who are the CROs under consideration to run each of these initiatives and how ma…

Thoughts on traunching this into 3x 100k phases?

Specifics of clinical strategy tbd. We have talked to a few CROs. We are looking to conduct the screen at a core facility at Washington University. We can include further details of the screen in the R&D plan

VDP-63 Anticancer and pro-longevity effects of high molecular weight hyaluronic acid (from naked mole rat to human) - Vera Gorbunova

Proposals Passed Proposals

longevion March 9, 2023, 12:51am 18

Update:

Topic		Replies	Views
VDP-106 [Governance] Proposal eligibility criteria to enter the VitaDAO deal-flow funnel Proposals	29	2877	July 6, 2023
VDP-16: Korolchuk Lab- Autophagy Activators Funding Proposal Passed Proposals	6	2715	December 22, 2021
VDP-103 [Funding]: Mutation-Specific Codon Suppression for Aging and Longevity Active Proposals	36	2482	July 19, 2023
VDP-122 [Assessment]: Ora Biomedical - Healthy Aging Therapies For Next Generation Medicine Proposals	14	1054	November 15, 2023
[VDP-40] Cellular ‘Soap’ For Infectious Disease Accelerated Aging - Dr Tim Peterson Passed Proposals	18	2359	May 2, 2022

VDP-63 Anticancer and pro-longevity effects of high molecular weight hyaluronic acid (from naked mole rat to human) - Vera Gorbunova

Related topics